Covid-19 Impact on Artificial Pancreas Device System Market, Global Research Reports 2020-2021

SKU ID :QYR-15636347 | Published Date: 08-May-2020 | No. of pages: 94
Sometimes an artificial pancreas device system is referred to as a "closed-loop" system, an "automated insulin delivery" system, or an "autonomous system for glycemic control."
Based on device type the market is segmented into control - to - range (CTR) system, threshold suspended device system and control - to - target (CTT) system.

This report provides a complete quantitative data and qualitative analysis on the global market for Artificial Pancreas Device System. Market size is analysed by country, product type, application, and competitors. Expanded coverage includes additional end-user industry breakdowns and in-depth producer profiles.
Prior to COVID-19, the global market for Artificial Pancreas Device System was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of xx% during 2021–2026, whereas post-COVID-19 scenario, the market for Artificial Pancreas Device System is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026.
This report covers market size and forecasts of Artificial Pancreas Device System, including the following market information:
Global Artificial Pancreas Device System Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
Global Artificial Pancreas Device System Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
Global Artificial Pancreas Device System Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
Global Artificial Pancreas Device System Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K Units)

Key market players
Major competitors identified in this market include Medtronic, Johnson & Johnson, TypeZero Technologies, Tandem Diabetes, Pancreum, Insulet, Beta Bionics, Animas Corporation, LLC, Bigfoot Biomedical, etc.

Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)

Based on the Type:
Control-to-Range (CTR) System
Threshold Suspended Device System
Control - to - Target (CTT) System

Based on the Application:
Hospital
Clinic
Others
  • PRICE
  • $3250
    $6500
    Buy Now

Our Clients